市場調查報告書
商品編碼
707237

全球細胞解離市場:產品,組織(結締組織,表皮組織),終端用戶,各地區(2018年∼2023年)

Cell Dissociation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球細胞解離市場在2018年到2023年整個預測期間內,預測將以12%的年複合成長率成長。

本報告提供全球細胞解離市場調查,提供市場概要,各產品·組織·終端用戶·地區別市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入廠商業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 成長要素
    • 生物醫藥品企業研究開發活動的擴大
    • 對癌症研究有利的資金籌措方案
  • 阻礙因素
    • 組織·細胞治療的成本高
  • 市場機會
  • 課題

第7章 市場分析:各市場區隔

  • 各產品
    • 酵素的解離產品
    • 非酵素的解離產品
    • 設備·週邊設備
  • 不同組織
    • 結締組織
    • 表皮組織
    • 其他組織
  • 各終端用戶
    • 製藥·生物科技企業
    • 學術研究機關
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第8章 企業簡介和競爭情形

  • American Type Culture Collection
  • Becton Dickinson & Company
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Himedia Laboratories
  • Merck KGaA
  • Miltenyi Biotec
  • Pan-Biotech
  • Stemcell Technologies
  • Thermo Fischer Scientific Inc.

第9章 市場未來展望

目錄
Product Code: 62794

The total worldwide R&D spending of pharmaceutical and biotechnology companies increased from USD 108 billion in 2006 to USD 141 billion in 2015. Investments in R&D activities may continue to increase but at half the former pace. As per the report from India Brand Equity Foundation, it is expected that R&D expenses will reach USD 160 billion in 2020.

The biopharmaceutical industry is a rapidly developing sector within the pharmaceutical industry, with enormous opportunities and implications for healthcare. Opportunities in biopharmaceuticals have been increasing over the past decade, as a result of great effectiveness and the safety of these drugs. Biopharmaceuticals offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure the diseases rather than merely treat the symptoms, which have significantly increased the demand for biopharmaceutical products.

Cell dissociation is an indispensable activity in biopharmaceutical research, as it is involved directly in drug development and pathology elucidation. Consequently, the increased spending by biopharmaceutical companies in R&D activities is driving the growth of the market studied.

Key Market Trends

Enzymatic Dissociation Products Segment is Expected to Witness a Healthy Growth

Cell and tissue dissociation, primary cell isolation, and harvesting of single cells are the principal applications for enzymes in stem cell research and cell biology studies. The use of enzymes for cell dissociation purposes is widespread. The goal of any dissociation procedure is to maximize the yield of functionally viable dissociated cells. The outcome of any dissociation procedure is dependent on (but not limited to) the type of tissue, age of animal/human, dissociation medium used, an enzyme used, enzyme concentration, temperature, and genetic modifications.

Consequently, a number of enzymes are used in research activities for various purposes. The most prominently used enzymatic dissociation products, in decreasing order of usage frequency, include trypsin, collagenase, elastase, and hyaluronidase, among others.

United States to Hold Significant Share of the Market

Sustained growth in pharmaceutical and biotechnology industries, increasing incidences of cancers and other chronic diseases, and a strong trend of R&D investments in life sciences by both industry and academia are the primary factors driving the growth of the market. In the United States, for the fiscal year 2016, USD 520 million was granted by the federal government for National Cancer Institute (NCI) budget, for breast cancer research, USD 800 million for clinical trials, USD 212 million for colorectal cancer research, USD 241 million for leukemia, and another cumulative amount in excess of USD 1 billion for research in other cancer types.

Additionally, the estimates available in the National Institute of Health portal for stem cell-based research indicate a cumulative funding budget of more than USD 3 billion for research in various fields of stem cell applications. Added to that, the presence of a large number of chemicals and chemical analysis providers in the United States, who are adept in supplying both enzymatic products and non-enzymatic products for cell dissociation, is further expected to drive the growth of the US cell dissociation market.

Competitive Landscape

The market studied is moderately competitive and several local, as well as international players, are posing intense competition across various geographies. Most of the key players of this market are having a good presence in the North America and Europe region. Germany, France, and Italy are some of the European countries where biotechnology companies are trying to establish their R&D plants. Similarly, the United States is a country where all the companies are generating large revenue due to the high adoption of the technologies and increasing use of cell dissociation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing R&D Activities in Biopharmaceutical Companies
    • 4.2.2 Favourable Funding Scenario for Cancer Research
  • 4.3 Market Restraints
    • 4.3.1 High cost of Tissue- and Cell-based Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Enzymatic Dissociation Products
    • 5.1.2 Non-enzymatic Dissociation Products
    • 5.1.3 Instruments and Accessories
  • 5.2 By Tissue
    • 5.2.1 Connective Tissue
    • 5.2.2 Epithelial Tissue
    • 5.2.3 Other Tissues
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Research and Academic Institutes
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 COMPANY PROFILES
    • 6.1.1 American Type Culture Collection
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 GE Healthcare
    • 6.1.5 Himedia Laboratories
    • 6.1.6 Merck KGaA
    • 6.1.7 Miltenyi Biotec
    • 6.1.8 Pan-Biotech
    • 6.1.9 Stemcell Technologies
    • 6.1.10 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS